Mesoblast Ltd (O:MESO) has reported impressive efficacy data from the first cohort of 18 February 2016 the Phase II trial of its mesenchymal precursor cell (MPC) product in rheumatoid arthritis (RA), ahead of full results due in Q316. Key catalysts next quarter will be the first interim analysis from the pivotal MPC-150-IM heart failure trial, together with an update to trial timelines following the halving of the trial to 600 patients. The launch of Temcell in Japan for graft vs host disease this quarter will bring a royalty stream from partner JCR Pharmaceuticals Co Ltd (T:4552). We lift our valuation to A$7.36 per share (from A$7.20).
To read the entire report Please click on the pdf File Below